Medical Patent News RSS Feed - Medical Patent News

Watson seeks FDA approval to market generic Beyaz

Watson seeks FDA approval to market generic Beyaz

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. [More]
KSU, St. Michael's receive U.S. patent to use BRCA1 gene for cardiovascular disease

KSU, St. Michael's receive U.S. patent to use BRCA1 gene for cardiovascular disease

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease. [More]

Apotex makes payment to Sanofi, Bristol-Myers Squibb to satisfy damages in Plavix patent litigation

Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case against Apotex. [More]

Watson settles ORTHO TRI-CYCLEN LO patent litigation with Janssen

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. on outstanding patent litigation related to Watson's generic version of Janssen's ORTHO TRI-CYCLEN LO (norgestimate/ethinyl estradiol) tablets. [More]

ConforMIS adds 22 patents to patient-specific implants and instrumentation systems portfolio

ConforMIS, Inc. today announced it has completed its most productive period to date in the development of its intellectual property with the addition of 22 issued patents to its portfolio since January 2011. [More]

Sandoz sends Remodulin Paragraph IV Notice Letter to United Therapeutics

United Therapeutics Corporation today announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz Inc. advising that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration requesting approval to market a generic version of the 10 mg/mL strength of Remodulin (treprostinil) injection. [More]
Precision receives U.S. patent allowance for genome engineering methods

Precision receives U.S. patent allowance for genome engineering methods

Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued Notices of Allowance for U.S. Patent Applications 13/246,270 and 13/246,346. [More]

Watson: ANDA for generic Lidoderm remains on track

In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc. today issued the following statement: Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track. [More]
BodyMedia sues BASIS Science over wearable body monitoring technology patent infringement

BodyMedia sues BASIS Science over wearable body monitoring technology patent infringement

BodyMedia, Inc., the leader in wearable body monitors, announced today that it has filed a patent infringement suit against BASIS Science, Inc. in the U.S. Federal District Court in Delaware for willfully infringing BodyMedia's breakthrough patented wearable body monitoring devices and sensor fusion technology. [More]
ImmunoCellular receives U.S. patent allowance for cancer stem cell treatment

ImmunoCellular receives U.S. patent allowance for cancer stem cell treatment

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company's method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells. [More]